Dimerix to Begin Work on Treatment for Diabetic Kidney Disease
Dimerix (ASX:DXB), a diabetes-focused biotech company, has signed a clinical trial agreement with the Australian Centre for Accelerating Diabetes Innovations (ACADI) to test its oral medicinal product DMX-200 in diabetic kidney disease patients. In addition ... [Read]
Scientific Advancements Spur Microcap Stock Growth
Two things are happening right now that investors should have on their radars. The first is that some microcap stocks are doing very well. This is evidenced in part by the iShares Microcap ETF (IWC) ... [Read]
Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting
– Nonclinical data demonstrate that a single intracochlear administration of an AAVAnc80 vector led to durable restoration of auditory function and was well tolerated, supporting planned clinical development of AK-OTOF for the treatment of OTOF ... [Read]
Inmagene Receives FDA IND Clearance for a Third Generation BTK Inhibitor Targeting Immunological Diseases
PR Newswire SAN DIEGO and SHANGHAI , May 15, 2022 /PRNewswire/ — Inmagene Biopharmaceuticals (“Inmagene”) announces that today the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application for the drug ... [Read]
Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting
Taxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss (alopecia) New non-clinical data demonstrate proof of principle that ALRN-6924 can temporarily arrest the cell cycle in human scalp hair follicles ... [Read]
Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting
REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced two poster presentations highlighting three of the Company’s gene ... [Read]
Tech Giants Commit Nearly $1 Billion Toward Carbon Capture
Some of the world’s largest companies are teaming up to commit nearly $1 billion in spurring the carbon-capture market. On April 12, Stripe, Facebook, Alphabet, Shopify and McKinsey & Co. Inc. announced the creation of ... [Read]
BridgeBio Pharma Announces Phase 2 Results From Acoramidis Study
BridgeBio Pharma (NASDQ:BBIO), a commercial-stage biopharmaceutical company developing medicines for patients suffering from genetic diseases and cancers with clear genetic drivers, recently reported updated results from its ongoing Phase 2 study for acoramidis. The study ... [Read]
Aprea (APRE) Reports FDA Removal of Clinical Hold on Study
Small biotech Aprea Therapeutics, Inc. APRE announced that the FDA has removed the full clinical hold on a study evaluating its lead product candidate, eprenetapopt (APR-246), in combination with other cancer drugs for treating lymphoid ... [Read]
Why Investors Should Hold on to Universal Health (UHS) Stock
Universal Health Services, Inc. UHS is well poised to grow on the back of accretive acquisitions and robust performance of behavioral health hospitals. Universal Health — with a market cap of $10.2 billion — is ... [Read]